A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Explore how chemotherapy causes peripheral neuropathy in 40% of cancer patients. Learn about the risk factors and the need ...

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released ...

Of those patients, 4,545 had painful and persistent nerve pain that ... induced peripheral neuropathy] is critical for promoting early diagnosis and developing personalized treatment strategies ...

Under this condition, which can result from traumatic injuries, infections, metabolic problems, or could be inherited due to ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

“Our findings emphasize that chronic painful chemotherapy-induced peripheral neuropathy ... or taxane chemotherapy drugs appear to pose the greatest risk for nerve pain, and lung cancer patients ...